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ABSTRACT 
SYNTHESIS AND BIOCHEMICAL EVALUATION OF HETEROARYL CJOC42 
DERIVATIVES FOR GANKYRIN BINDING 
Daniel (Yi-Chih) Juang 
 
Gankyrin is an oncogenic protein directly involved in various biological processes, such as 
cellular growth, cell cycle progression, cell proliferation, and invasion. Gankyrin 
overexpression has been observed in many cancer types, and gankyrin either directly or 
indirectly regulates key biochemical pathways related to cancer progression through its 
various protein-protein interactions (PPIs). Gankyrin interacts with retinoblastoma protein 
(pRb), cyclin-dependent kinase 4 (CDK4), mouse double minute2 (MDM2) and the S6 
ATPase of the 19S regulatory cap of the 26S proteasome. Each of these PPIs controls the 
degradation of key tumour suppressor proteins, which in turn controls cell proliferation, 
migration and metastasis. Overexpression of gankyrin in cancer cells is directly linked to 
these cellular activities. The first non-peptide-based small inhibitor, cjoc42, was 
discovered in 2016 and inhibited the binding of gankyrin and the S6 ATPase of the 26S 
proteasome leading to diminished proliferation in certain cancers. Despite this advance, 
cjoc42 has 2 major flaws: low binding affinity and poor water solubility. In order to 
improve on the cjoc42 scaffold and address these issues, a series of heterocycles were 
introduced to the cjoc42 scaffold. Herein we describe the synthesis and biological 
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1.1: Protein-protein interactions (PPIs) 
 Protein-protein interactions (PPIs) are crucial in cells and living organisms to their 
proper functioning. It occurs when protein molecules physically interact with each other at 
specific binding regions. These interactions play important roles in many cellular functions, 
such as: cell cycle control, cell to cell interaction, metabolic processes, and cellular 
development.1 At a molecular level, PPIs regulate cell-to-cell communication, receptor-
ligand interactions, signal transduction pathways, gene transcription, and proliferation.2 
Aberrant behaviour of these PPIs has been linked to the onset and development of 
numerous types of cancers as well as other diseases, where cancer is when cells 
uncontrollably divide, proliferate, and spread to other regions of the body.3 Therefore, PPIs 
have become a target for anticancer therapeutic strategies due to our fuller understanding 
of their cancer biology.4  
Challenges and concerns have long been known when targeting PPIs despite being 
an attractive anticancer strategy. Some of these challenges include: large PPI interface 
areas, lack of a deep binding region, close or adjacent binding regions, and a lack of natural 
ligands as PPI inhibitors.4 Despite these challenges, great advances have been made in this 
area with some PPI-targeting compounds currently in clinical trials. For example, ABT-
737 (Figure 1.) is a small molecule inhibitor of the Bcl-2/BAK interaction, which has 
shown to be cytotoxic to multiple myeloma cell lines.5 ABT-263 (Figure 1.) and ABT-199 
(Figure 1.) are also small molecule inhibitors currently in clinical trials which target  Bcl-
2-BAK interaction/ in certain tumors.6,7 17-AAG (Figure 1.) is a potent inhibitor of the 
heat shock protein 90/HIF1α interaction, which is used for the treatment of HER-2 positive 
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metastatic breast cancers.8 The nutlin family of compounds are small molecule inhibitors 
of the mouse double minute 2 homolog (MDM2)/p53 interaction for the treatment of 
multiple myeloma.9   These examples have demonstrated that small molecule inhibitors are 









 Gankyrin is an oncogenic protein that is involved in multiple PPIs which regulates 
various other cellular activities such as: cellular growth, cell cycle progression, 
proliferation, and invasion. Higashitsuji et al, identified the gene for gankyrin which is 
frequently overexpressed in cancerous hepatocytes.10 Initially it was found that gankyrin 
binds to retinoblastoma protein (pRb), increasing its phosphorylation and subsequent 
degradation, resulting in increased cell growth which contributes to 
hepatocarcinogeneses.11   
 Gankyrin principally is a component of the 26 S proteasome and consists of 7 
ankyrin repeats in its sequence while containing 226 amino acids resulting in a 25-kDa 
protein. Gankyrin is a regulatory subunit of the 26S proteasome which interacts with its S6 
ATPase subunit. Gankyrin’s function as a chaperone for the 26S proteasome is crucial in 
the proteasomal degradation of certain proteins. 
 Two key proteins which gankyrin directly interacts with are the tumour suppressor 
proteins retinoblastoma protein (pRb) and p53. Phosphorylation of pRb by cyclin-
dependent kinase 4 (CDK4) is regulated by gankyrin, and ubiquitylation of p53 by MDM2 
is enhanced by gankyrin.12 pRb and p53 are both tumour suppressor proteins, and they 
function to inhibit cell proliferation and tumour development in normal cells. Recent 
studies have shown that overexpression of gankyrin is related to various cancer types. 
Specifically, overexpression of gankyrin is observed in cervical cancer13, breast cancer14, 
oesophageal squamous cell carcinoma (ESCC)15, gastric cancer16 as well as other cancer 
types. This finding in combination with evidence in the next section suggests demonstrates 
that gankyrin is important in numerous cancers. This demonstrates that gankyrin is 
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important to the progression of numerous human cancers and exhibits great promise as a 
therapeutic target for multiple cancer types. 
 
1.2.1: The gankyrin-proteasome interaction 
 The 26S proteasome is a large ATP-dependent protease complex involved in the 
degradation of ubiquitin-tagged proteins.17 It consists of two sub-complexes, a 20S core 
particle and a 19S regulatory particle (Figure 2). It is responsible for many essential 
cellular processes which include: DNA replication, transcription, cell cycle maintenance, 
stress responses and signal transduction.18 Gankyrin is a chaperone of the 26S proteasome 
( Figure 2) and regulates various oncogenic signalling pathways in cancer cells by 
controlling the proteasomal degradation of numerous tumour suppressor proteins (e.g., pRb 
and p53). The 19S regulatory particle of the 26S proteasome consists of regulatory ATPase 
complexes which use the chemical energy from ATP hydrolysis to unfold proteins and 
shuttle them into the proteases’ active site for degradation. The C-terminal portion of the 
S6 ATPase from the 26S proteasome is specifically responsible for interacting with 
gankyrin. Cells which overexpress gankyrin exhibit an increase in the degradation of pRb19, 
p53 and other tumour suppressor proteins which ultimately leads to rapidly proliferating 





Figure 2. Structure and Subunits of the 26S Proteasome (Left). Gankyrin Binding of the 










1.2.2: Gankyrin’s ability to bind and regulate pRb 
pRb is a tumour suppressor protein which plays a role in controlling tumour 
progression as well as regulating the cell cycle.20 Overexpressed gankyrin binds to CDK4 
and pRb, resulting in increased phosphorylation and subsequent degradation of pRb.19 pRb 
levels are typically regulated by CDK4 phosphorylation which inactivates the pRb’s 
function.21 However, gankyrin overexpression enhances phosphorylated pRb degradation 
as well as further promoting pRb phosphorylation by activating CDK4.22 The relationship 
between pRb, CDK4, and gankyrin is shown in in Figure 3a and 3c. Overactive CDKs are 
present in most cancer cells, and CDK both phosphorylates and inactivates pRb in normal 
and cancer cells.23 . Gankyrin competes with p16 for binding CDK4, where p16 typically 
inhibits CDK4-mediated phosphorylation of pRb.24 Therefore, overexpression of gankyrin 
negatively regulates pRb both directly and indirectly, which in turn enhances cell cycle 




Figure 3. Gankyrin’s Regulation of Tumour Suppressor Protein Degradation. (a) CDK4 
Controls Phosphorylation of pRb. (b) MDM2 Regulates Ubiquitination of p53. 
(c) Elevated Gankyrin Levels Enhances Phosphorylation of pRb by Activating 
CDK4 and Enhances p53 Ubiquitination by Activating MDM2, leading to an 




1.2.3: Gankyrin-mediated degradation of p53 
 Gankyrin also regulates p53 levels by binding to and activating MDM2, which is a 
negative regulator of p53, a protein that regulates the cell cycle. (Figure 3b). p53 also 
controls a vast range of cellular processes by regulating ~500 target genes.25 The gankyrin-
MDM2 interaction ultimately facilitates p53-MDM2 binding, which increases the 
ubiquitylation and subsequent degradation of p53 by the 26S proteasome.26, 27 Furthermore, 
ubiquitylated p53 is shuttled to the proteasome by gankyrin for subsequent degradation 
(Figure 3c). The indirect involvement of gankyrin in diminishing p53 levels ultimately 
results in uncontrolled cell growth, increased cell proliferation, negative regulation of 
apoptosis28 and cancer progression in cancer cells. 
 
1.2.4: Other gankyrin-based PPIs 
Gankyrin is primarily involved in the degradation of pRb and p53, however, it also 
interacts with various other proteins. RelA, or transcription factor p65, can directly bind 
gankyrin, which in turn regulates the cellular inflammation which often precedes different 
cancers.29 Gankyrin also binds to hepatocyte nuclear factor 4α (HNF4α), a nuclear 
transcription factor and tumour suppressor protein that is crucial for liver development and 
regulating liver cancer development. 30 Overexpressed gankyrin in hepatocellular 
carcinoma (HCC) cells competes for NRF2 binding with KEAP1, which inhibits 
proteasomal degradation of NRF2.31 Disruption of the interaction between KEAP1 and 
gankyrin is a potential therapeutic target against HCC.32 PPIs that involve gankyrin 
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regulate many cellular processes and pathways demonstrating the importance of research 
aimed at gaining a fuller understanding of gankyrin’s biological role. 
 
1.2.5: Overexpression of gankyrin in specific cancer types 
Gankyrin is an important regulator of key cancer hallmarks such as: carcinogenesis, 
proliferation and metastasis. From its role in various cellular metabolic pathways, gankyrin 
overexpression also has a positive correlation with metastasis, proliferation and migration. 
Cell signalling pathways such as Wnt/β-Catenin, NF-κB, STAT3/Akt, IL-1β/IRAK-1 and 
RhoA/ROCK have all been found to be regulated by gankyrin.33 
 Gankyrin plays different roles in different types of cancers. In colorectal cancer, 
gankyrin regulates mTORC1 signalling and the PI3K/GSK-3β/β-catenin pathway, which 
promotes carcinogenesis and progression.34 In gastric cancer, gankyrin activates the 
PI3K/AKT signalling pathway which promotes cancer cell proliferation.35 Gankyrin also 
has an important role in cholangiocarcinoma by activating the IL-6/STAT3 signalling 
pathway through down-regulation of pRb.36 
This active and prominent role in multiple cancer types shows gankyrin’s important 
oncogenic roles, and therefore developing specific therapeutics for gankyrin 




1.3: Gankyrin-binding molecules 
There have been 3 primary methods utilized for developing gankyrin-targeting 
small molecules:  synthesized protein-based inhibitors, peptide-based inhibitors and non-
peptide-based small molecule inhibitors. The first gankyrin-binding molecule was 
identified as a synthetic derivative of the S6 ATPase of the 26S proteasome.37 This 
molecule also demonstrated excellent binding affinity (Kd = 21 nM) and was able to disrupt 
the gankyrin-26S proteasome interaction. However, protein based inhibitors are often too 
large in size to be developed as appropriate therapeutics and also possess poor membrane 
permeability as well as metabolic stability.38 The first and only peptide-based inhibitor was 
developed in 2014. This peptide, amino acid sequence of EEVD (Figure 4a), was a key 
sequence of the S6 ATPase of the 26S proteasome for gankyrin binding, and this peptide 
inhibits the binding of the S6 ATPase with gankyrin.  Despite this finding, EEVD was 
found to require high concentrations for effectively binding gankyrin, and peptide-based 
inhibitors typically are found to lack metabolic stability and cell permeability, suggesting 
that another approach was necessary for targeting gankyrin. 
 
Figure 4. a.) Structure of the First Peptide-Based Gankyrin Binder EEVD. b.) Structure 
of the First Non-Peptide Based Small Molecule Binder of Gankyrin, cjoc42. 
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In 2016, cjoc42 (Figure 4b), the first non-peptide based small molecule binder of 
gankyrin, was discovered. It was discovered from a high throughput screen in 2016 and it 
was the very first small molecule binder of gankyrin (Kd of 630 nM) which also prevents 
gankyrin binding with the 26S proteasome. The ability of cjoc42 to bind gankyrin was 
confirmed through the use of various experiments: thermal shift assay, microscale 
thermophoresis (MST) and isothermal calorimetry (ITC).39 In addition, a chemical shift 
change from NMR studies of cjoc42 binding gankyrin suggested that cjoc42 binds to the 
specific site on gankyrin where it interacts with the 26S proteasome.39 In U2OS and HepG2 
cancer cell lines, cjoc42 was able to restore p53 levels, indicating disruption of the 
gankyrin-26S proteasome interaction.39 This finding suggested that cjoc42 may show 
promise in inhibiting cancer cell proliferation in certain cancer types.40 A follow up study 
showed that cjoc42 can indeed inhibit cancer cell proliferation in huh6 and hep1c1c7 
hepatoblastoma cell lines.40 In addition, this inhibition of proliferation was linked to 
increased p53, pRb and other tumour suppressor protein levels, against suggesting cjoc42 
disrupts the gankyrin-26S proteasome interaction. With these findings, cjoc42 has 
demonstrated promise for targeting gankyrin and treating certain cancers. However, cjoc42 
displays relatively weak gankyrin binding and poor water solubility. This provided an 
opportunity to continue to optimize the cjoc42 scaffold for gankyrin binding and water 
solubility.  
The equilibrium dissociation constant (Kd) is a basic parameter utilized to evaluate 
the binding properties of  a drug to a particular target.41 The lower the Kd value, the better 
the binding affinity., A typical Kd value for a particular drug varies depending on the class 
of drugs and their respective targets. For example, a Kd value of 1 mM could be considered 
13 
 
as high affinity in metabolic regulation, while it could be considered as low affinity in 
antibody design42. From the literature, the binding affinities of topoisomerase inhibitors 
have a range of Kd values from 6-550 nM, depending on the particular drug class
43, 




1. Replacing the aryl triazole moiety of cjoc42 with heteroaryl triazole groups will 
improve water solubility while maintaining or improving gankyrin binding.  
2. Replacing the tosyl group of cjoc42 with heteroaryl amides will improve water 
solubility while maintaining or improving gankyrin binding. 
 
1.5: Design Rationale 
As described earlier, cjoc42 has demonstrated promise as a gankyrin-binding 
therapeutic, but demonstrates poor gankyrin binding as well as poor water solubility. 
Therefore, these deficiencies became the focal points for this project. Cjoc42 (Figure 4b) 
contains a methyl benzoate group, triazole ring, p-tosylate group, and a propyl group linker. 
The methyl benzoate and p-tosylate were thought to be replaced with heteroaromatic ring 
systems to improve gankyrin binding while also improving water solubility. This enhanced 
binding could be achieved by improving hydrogen bonding with R41 due to the presence 
of more polar aromatic heterocycles in these cjoc42 derivatives (Figure 5, Top). Factors 
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that could influence molecule binding includes electronic, steric or hydrogen bonding, 
therefore changing these factors could alter biochemical properties of cjoc42.  
Previous work in our group was aimed at improving the metabolic stability of 
cjoc42, therefore a series of sulfonate ester replacements were synthesized and evaluated. 
From this, an amide group (JA-1-33, Figure 5) was found to be a suitable replacement by 
maintaining similar gankyrin binding to the sulfonate ester of cjoc42, while presumably 
also increasing metabolic stability. Both amides and sulphonate esters could potentially 
undergo hydrolysis by a similar mechanism, however the reaction with an amide is much 
slower44.  
The amide bond is considered a very non-reactive and stable functional group due 
to its ability to delocalize its electrons to the nitrogen, carbon, and oxygen atoms, which in 
turn makes the bond less polar and less susceptible to nucleophilic attack.45 Sulphonate 
ester groups, however, are susceptible to nucleophilic attack46, therefore replacing this 
functional group with the more stable amide could improve the overall stability of our next 
generation cjoc42 derivatives. The previously synthesized cjoc42 derivative JA-1-33 
(Figure 5) containing an amide replacement for the sulphonate ester displayed similar 
gankyrin binding affinity to cjoc42. Therefore, with similar gankyrin binding and 
potentially enhanced metabolic stability, the amide replacement was decided to be suitable 
for future derivatives. The binding affinity of cjoc42 derivatives were evaluated in a protein 
thermal shift assay. The solubility of cjoc42 derivatives were predicted by a clogP value, 





Figure 5. Top: Proposed binding of cjoc42 with gankyrin by molecular modelling. PDB: 
2DVW. Bottom: Proposed Derivatives of cjoc42 (compounds 23-30 and 16-20) 




2. Experimental section 
2.1: General chemistry 
All reagents were directly used from commercial sources without further 
purification. Solvents used in all parts of chemistry and column chromatography were more 
than 99% pure and are also from commercial sources. A 400 MHz nuclear magnetic 
resonance spectrometer (NMR) were used for all proton (1H) and carbon (13C) spectra. A 
chemical shift of 2.5 ppm was used for residual DMSO-d6 and a chemical shift of 7.26 ppm 
was used for residual CDCl3 in all proton NMR spectra. Data are reported as follows: 
chemical shift (multiplicity [singlet (s), doublet (d), doublet of doublets (dd), doublet of 
doublets of doublets (ddd), triplet (t), quartet (q), quintet (p), sextet (h), multiplet (m)], 
coupling constants [Hz], integration). Carbon chemical shifts are reported in ppm with the 
respective solvent resonance as the internal standard (DMSO-d6, 39.52 ppm or CDCl3, 77.2 
ppm). All NMR spectra were acquired at ambient temperature. Analytical thin-layer 
chromatography (TLC) was performed using Silica Gel 60 Å F254 precoated plates (0.25 
mm thickness). Monitoring reactions by TLC or column chromatography were visualised 
by UV absorption with ether wavelength of 254 nm or 365 nm. HPLC was performed by 
normal phase column or reverse-phase C18 column with UV detector. Specifications for 
Ultra high performance LC.MS to collect mass spectrometry data are: reverse-phase C18 
column (1.7 μm particle size, 2.1 x 50 mm), dual atmospheric pressure chemical ionization 





2.2: HPLC Analysis 
Agilent Eclipse plus C18 from Agilent 1260 infinity series HPLC system (Agilent, Santa 
Clara, CA) was used to analyse the purity of synthesised compounds, where 3.5 μm, 4.6 
mm × 100 mm column were used and the runs were monitored at 254 nm. Target 
compounds were aimed to be at least 95% pure. The mobile phase consists of acetonitrile 
(ACN) and water (0.1% DEA). All gradient trials were run with various ratio of ACN and 
water for 10 minutes with the flow rate of 0.5 mL/minute for analysis of (16, 23-25, 27). 
For compounds (17-20, 26, 28-30) were analysed by UPLC. XBridge ® BEH shield RP 
2.5 μm (3.0 x 100 mm) (Waters, MA, USA) column was used for UPLC analysis, where 
the runs were monitored at 254 nm for 5 minutes with flow rate of 0.5 ml/minute. Various 
ratios of acetonitrile (ACN) and water (0.1% FA) were used for the mobile phase. 
 
2.3: LC/MS Analysis 
Agilent Technologies 1260 infinity series LC were used for LR-LC/MS analysis, and all 
runs were performed on a single quadrupole. The following specifications were used on all 
runs for analysis: Column = Agilent Poroshell 120 EC-C18 2.7 μm, 4.6 x 50 mm.; 
temperature = 300 K; solvent acetonitrile/water 70:30 (0.1% formic acid): flow rate 0.5 






2.4: General Synthetic Methods 
2.4.1: General synthetic procedure for azide intermediates (6-8) 
To a stirred solution of 2-aminothiazole in HCl (6M, 1.2 eq) at 0˚C was added sodium 
nitrite (1.2 eq). The reaction mixture was stirred for 30 minutes at 0˚C, followed by addition 
of sodium azide (1.2 eq), and then the reaction mixture was stirred for an additional 15 
minutes at room temperature. Upon completion, the reaction mixture was partitioned 
between the ethyl acetate and aqueous layers. The organic layer was then dried over sodium 
sulphate, filtered and removed under reduced pressure to obtain desired products 6-8 which 
were all immediately used in the next step without purification or further analysis. 
 
2.4.2: 3-Azidopyridine (6) 
 
 
2.4.3: 2-Azidothiazole (7) 
 
 




2.4.5: 4-Azidopyridine (9) 
 
To a stirred solution of 4-bromopyridine (1 eq) in EtOH/H2O (1:1) was added NaOH (0.5 
eq) and NaN3 (2.3 eq), and the reaction mixture was stirred overnight at 100˚C. Upon 
completion, the reaction mixture was partitioned between the ethyl acetate and aqueous 
layers. The organic layer was then dried over sodium sulphate, filtered and removed under 
reduced pressure to obtain the desired product.47 Yields were not obtained due to the 
instability of these compounds, therefore, the synthesised azide intermediates were used 
immediately for the next reaction. 
 
2.4.6: 2-Azidopyridine (10) 
 
To a stirred solution of 2-chloropyridine (1 eq) in DMF was added NH4Cl (2 eq) and NaN3 
(2 eq), and the reaction mixture was stirred overnight in a pressure chamber at 110˚C. Upon 
completion, the reaction mixture was partitioned between ethyl acetate and the aqueous 
layer. The organic layer was then dried over sodium sulphate, filtered and removed under 
reduced pressure to obtain desired product.48 Yields were not obtained due to the instability 
of these compounds, therefore, the synthesised azide intermediates were used immediately 




 2.4.7: General synthetic procedure for intermediates (11-15) 
 
Ar = various aromatic heterocycles 
Azides 6-10 (1 eq) were each dissolved in a THF/t-BuOH/ water (2:3:5) mixture, to which 
4-pentyn-1-ol (1 eq), copper sulphate (0.3 M, 0.3 eq), and sodium ascorbate (0.1 M, 0.01 
eq) were added. The reaction mixture was then stirred overnight at room temperature. Upon 
completion, the reaction mixture was partitioned between ethyl acetate and water, and then 
washed 3 times with water. The organic layer was then dried over sodium sulphate, filtered 
and concentrated under reduced pressure to obtain desired alcohol intermediate (11-15) in 
varying yields (3-42%). 
 
2.4.8: 3-(4-(3-hydroxypropyl)-1H-1,2,3-triazol-1-yl)pyridine (11) 
 
(371mg, 22%). 1H NMR (400 MHz, DMSO-d6) δ= 9.12 (d, J = 2.5 Hz, 1H), 8.67 (d, 2H), 
8.30 (ddd, J = 8.3, 2.5, 1.4 Hz, 1H), 7.64 (dd, J = 8.3, 4.8 Hz, 1H), 4.55 (s, 1H), 3.49 (t, J 
= 6.3 Hz, 2H), 2.76 (t, 2H), 1.87 – 1.77 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ= 





2.4.9: 4-(4-(3-hydroxypropyl)-1H-1,2,3-triazol-1-yl)pyridine (12) 
 
(314mg, 42%). 1H NMR (400 MHz, DMSO-d6) δ= 8.80 – 8.74 (m, 3H), 7.95 (d, J = 6.3 
Hz, 2H), 4.55 (t, J = 5.0 Hz, 1H), 3.48 (m, 2H), 2.76 (t, J = 7.7 Hz, 2H), 1.87 – 1.78 (m, 
2H). 13C NMR (100 MHz, DMSO-d6) δ= 149.14, 148.95, 144.79, 120.49, 114.25, 59.89, 
31.84, 21.59. 
 
2.4.10: 2-(4-(3-hydroxypropyl)-1H-1,2,3-triazol-1-yl)thiazole (13) 
 
(76mg, 3%). 1H NMR (400 MHz, DMSO-d6) δ= 8.64 (s, 1H), 7.81 (d, J = 3.4 Hz, 1H), 
7.74 (d, J = 3.4 Hz, 1H), 4.55 (t, J = 5.1 Hz, 0H), 3.46 (q, J = 11.7, 6.0 Hz, 2H), 2.76 (t, J 
= 7.7 Hz, 2H), 1.86 – 1.76 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 156.92, 148.64, 








2.4.11: 2-(4-(3-hydroxypropyl)-1H-1,2,3-triazol-1-yl)pyridine (14)  
 
(177mg, 10%). 1H NMR (400 MHz, DMSO-d6) δ 8.62 – 8.56 (m, 2H), 8.12 – 8.07 (m, 2H), 
7.53 (s, 1H), 4.55 (t, J = 5.1 Hz, 1H), 3.47 (q, J = 11.4, 6.2 Hz, 2H), 2.76 (t, J = 7.7 Hz, 
2H), 1.86 – 1.77 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 148.81, 148.67, 148.05, 
139.95, 123.93, 118.87, 113.44, 59.98, 32.03, 21.61.  
 
2.4.12: General synthetic procedure for sulfonate esters (16-20) 
To a stirred solution of the desired alcohol intermediate (11-15, 1 eq) in dichloromethane 
(10 mL) at 0˚C was added triethylamine (1 eq) and 4-dimethylaminopyridine (0.1 eq). p-
tosyl chloride (1.5 eq) was then added and the reaction mixture was stirred for an additional 
15 minutes at 0˚C, followed by stirring overnight at room temperature. Upon completion, 
the reaction mixture was partitioned between dichloromethane and water. The organic 
layer was then washed 3 times with water, dried over sodium sulfate, filtered, and removed 
under reduced pressure. The desired sulphonate esters (16-20) were then purified using 







2.4.13: 2-(4-(3-(tosyloxy) propyl)-1H-1,2,3-triazol-1-yl)methoxypyridine (16) 
 
(22 mg, 13%). 1H NMR (400 MHz, CDCl3) δ= 8.41 (d, J = 2.8 Hz, 1H), 7.91 (dd, J = 8.9, 
2.8 Hz, 1H), 7.76 (d, J = 8.0 Hz, 2H), 7.63 (s, 1H), 7.32 (d, J = 8.0 Hz, 2H), 6.87 (d, J = 
8.9 Hz, 1H), 4.07 (t, J = 6.0 Hz, 2H), 3.98 (s, 3H), 2.86 (t, J = 7.3 Hz, 2H), 2.41 (s, 3H), 
2.15 – 2.06 (m, 2H). 13C NMR (100 MHz, CDCl3) δ= 164.22, 146.98, 145.12, 139.20, 
133.10, 132.20, 130.10, 128.59, 128.11, 120.23, 112.00, 69.51, 54.31, 28.43, 21.84, 21.56. 
tR=8.2 min, 96%. 
 
2.4.14: 4-(4-(3-(tosyloxy) propyl)-1H-1,2,3-triazol-1-yl)pyridine (17)  
 
(34 mg, 19%). 1H NMR (400 MHz, DMSO-d6) δ= 8.78 (d, J = 6.3 Hz, 2H), 8.74 (s, 1H), 
7.92 (d, J = 6.4 Hz, 2H), 7.78 (d, J = 8.3 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 4.10 (t, J = 6.2 
Hz, 2H), 2.73 (t, J = 7.5 Hz, 2H), 2.35 (s, 3H), 2.05 – 1.96 (m, 2H). 13C NMR (100 MHz, 
DMSO-d6) δ= 151.60, 147.17, 144.86, 142.59, 132.28, 130.12, 127.57, 120.31, 113.32, 





2.4.15: 3-(4-(3-(tosyloxy) propyl)-1H-1,2,3-triazol-1-yl)pyridine (18) 
 
(53 mg, 30%). 1H NMR (400 MHz, DMSO-d6) δ= 9.09 (d, J = 2.4 Hz, 1H), 8.68 (d, J = 
3.5 Hz, 1H), 8.61 (s, 1H), 8.28 (d, J = 8.3 Hz, 1H), 7.78 (d, J = 8.2 Hz, 2H), 7.65 (dd, J = 
8.3, 4.8 Hz, 1H), 7.44 (d, J = 8.1 Hz, 2H), 4.11 (t, J = 6.2 Hz, 2H), 2.73 (t, J = 7.5 Hz, 2H), 
2.35 (s, 3H), 2.05 – 1.96 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ= 149.46, 146.82, 
144.87, 141.01, 133.32, 132.32, 130.13, 127.58, 124.60, 120.70, 69.97, 27.73, 21.02, 20.86. 
tR=1.1 min, 96%. 
 
2.4.16: 2-(4-(3-(tosyloxy) propyl)-1H-1,2,3-triazol-1-yl)pyridine (19)  
 
(47 mg, 27%). 1H NMR (400 MHz, DMSO-d6) δ= 8.60 (d, J = 4.0 Hz, 1H), 8.53 (s, 1H), 
8.10 (q, J = 16.1, 8.5 Hz, 2H), 7.77 (d, J = 7.9 Hz, 2H), 7.53 (t, J = 5.5 Hz, 1H), 7.43 (d, J 
= 8.0 Hz, 2H), 4.08 (t, J = 6.3 Hz, 2H), 2.73 (t, J = 7.6 Hz, 2H), 2.35 (s, 3H), 2.05 – 1.96 
(m, 2H). 13C NMR (100 MHz, DMSO-d6) δ= 148.87, 148.56, 146.53, 144.85, 140.04, 





2.4.17: 2-(4-(3-(tosyloxy) propyl)-1H-1,2,3-triazol-1-yl)thiazole (20) 
 
(69 mg, 57%). 1H NMR (400 MHz, DMSO-d6) δ= 8.57 (s, 1H), 7.82 (dd, J = 3.5, 0.9 Hz, 
1H), 7.80 – 7.74 (m, 3H), 7.44 (d, J = 8.0 Hz, 2H), 4.08 (t, J = 6.2 Hz, 2H), 2.73 (t, J = 7.5 
Hz, 2H), 2.37 (s, 3H), 2.05 – 1.96 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ= 156.80, 
147.10, 144.88, 140.56, 132.25, 130.12, 127.57, 119.88, 119.54, 69.86, 27.46, 21.04, 20.73. 
tR=0.35 min, 99%. 
 
2.4.18: Synthesis of carboxylic acid intermediate - Methyl 4-(4-(4-butanoic acid)-1H-
1,2,3-triazol-1-yl)benzoate (22) 
 
To a stirred solution of 4-azido benzoic acid (21, 1 eq) in 20 mL methanol was added 3 
drops of concentrated sulfuric acid at room temperature. The reaction was then heated to 
reflux and stirred overnight at 90°C. Upon complete consumption of the acid, the solvent 
was removed under reduced pressure. The residue was then re-dissolved in ethyl acetate 
and washed 3 times with 1M NaOH. The organic layer was then dried over sodium sulphate, 
filtered, and concentrated in vacuo to afford the desired ester without further purification 
as a yellow solid (94%). Methyl 4-azido benzoate (1 eq) was then dissolved in a THF/t-
BuOH/ water (2:3:5) mixture, to which 5-hexynoic acid (1 eq), copper sulphate (0.3 M, 0.3 
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eq), and sodium ascorbate (0.1 M, 0.01 eq) were added. The reaction mixture was then 
stirred overnight at room temperature. Upon completion, the reaction mixture was 
partitioned between ethyl acetate and water and then washed 3 times with water. The 
organic layer was then dried over sodium sulphate, filtered and concentrated under reduced 
pressure to obtain the desired carboxylic acid intermediate 22 in 65% yield. 
 
2.4.19: General synthetic procedure for the formation of amides (23-30) 
To a stirred solution of carboxylic acid 22 (1 eq) in dichloromethane (10 mL) at room 
temperature was added the desired arylamine 1-5 (1.5 eq), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (2.1 eq) and pyridine (2.1 eq) or 4-
dimethylaminopyridine (2.1 eq). The reaction mixture was then stirred overnight at room 
temperature. Upon completion, the reaction mixture was partitioned between 
dichloromethane and water. The organic layer was then washed 3 times with water, dried 
over sodium sulphate, filtered and removed under reduced pressure. The desired amides 
were then purified using either column chromatography, preparative thin layer 
chromatography, or reverse phase column chromatography if necessary, to obtain amides 







2.4.20: Methyl 4-(4-(3-(N-3-pyridinylamido)propyl)-1H-1,2,3-triazol-1-yl)benzoate 
(23) 
 
(28.9 mg, 46%). 1H NMR (400 MHz, DMSO-d6) δ= 10.40 (s, 1H), 8.79 (d, J = 14.5 Hz, 
2H), 8.22 (dd, J = 4.7, 1.5 Hz, 1H), 8.14 (d, J = 8.8 Hz, 2H), 8.11 – 8.04 (m, 3H), 7.31 (dd, 
J = 8.3, 4.7 Hz, 1H), 4.13 (q, J = 5.3 Hz, 1H), 3.89 (s, 3H), 3.16 (d, J = 5.2 Hz, 2H), 2.79 
(t, J = 7.5 Hz, 2H), 2.06 – 1.96 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ= 171.37, 165.31, 
147.92, 143.90, 140.68, 139.91, 135.82, 130.92, 129.00, 125.88, 123.50, 120.43, 119.51, 
52.31, 35.42, 24.46, 24.38. tR=3.8 min, 96%. 
 
2.4.21: Methyl 4-(4-(3-(N-4-pyridinylamido)propyl)-1H-1,2,3-triazol-1-yl)benzoate 
(24) 
 
(23.9 mg, 38%). 1H NMR (400 MHz, DMSO-d6) δ= 11.04 (s, 1H), 8.85 (s, 1H), 8.42 (d, J 
= 6.3 Hz, 2H), 8.12 (q, J = 17.7, 8.8 Hz, 4H), 7.72 (d, J = 6.5 Hz, 2H), 3.88 (s, 3H), 3.15 
(s, 1H), 2.78 (t, J = 7.4 Hz, 2H), 2.54 (t, J = 7.5 Hz, 2H), 2.06 – 1.96 (m, 2H). 13C NMR 
(100 MHz, DMSO-d6) δ= 172.05, 165.26, 149.87, 147.82, 145.84, 139.86, 130.85, 128.98, 




2.4.22: Methyl 4-(4-(3-(N-4-pyridinylamido)propyl)-1H-1,2,3-triazol-1-yl)benzoate 
(25) 
 
(39 mg, 31%). 1H NMR (400 MHz, CDCl3) δ= 8.30 – 8.15 (m, 4H), 7.92 – 7.80 (m, 4H), 
7.74 – 7.66 (m, 1H), 7.07 – 7.00 (m, 1H), 3.96 (s, 3H), 2.93 (t, J = 7.2 Hz, 2H), 2.54 (t, J 
= 7.2 Hz, 2H), 2.25 – 2.14 (m, 2H). 13C NMR (100 MHz, CDCl3) δ= 171.99, 166.19, 155.22, 
151.06, 148.33, 140.41, 131.54, 130.21, 119.97, 119.86, 119.47, 114.91, 52.64, 36.83, 
24.98, 24.83, 18.66. tR=5.0 min, 96%. 
 
2.4.23: Methyl 4-(4-(3-(N-2-thiazolamido)propyl)-1H-1,2,3-triazol-1-yl)benzoate (26) 
 
(66.5 mg, 52%). 1H NMR (400 MHz, CDCl3) δ= 8.17 (d, J = 8.6 Hz, 2H), 7.85 (s, 1H), 
7.80 (d, J = 8.6 Hz, 2H), 7.39 (d, J = 3.7 Hz, 1H), 6.93 (d, J = 3.6 Hz, 1H), 3.94 (s, 3H), 










(32 mg, 23%).1H NMR (400 MHz, CDCl3) δ= 8.51 (s, 1H, NH), 8.24 (s, 1H), 8.16 (d, J = 
8.5 Hz, 2H), 7.93 (d, J = 8.9 Hz, 1H), 7.87 (s, 1H), 7.78 (d, J = 8.5 Hz, 2H), 6.68 (d, J = 
8.9 Hz, 1H), 3.93 (s, 3H), 3.87 (s, 3H), 2.89 (t, J = 6.9 Hz, 2H), 2.47 (t, J = 7.0 Hz, 2H), 
2.17 – 2.08 (m, 2H). 13C NMR (100 MHz, CDCl3) δ= 171.59, 166.08, 161.01, 148.46, 
140.20, 138.57, 132.31, 131.55, 130.38, 129.18, 119.95, 119.63, 110.65, 53.75, 52.67, 
36.06, 25.64, 24.35. tR=4.8 min, 98%. 
 
2.4.25: Methyl 4-(4-(3-(N-2-oxazolamido)propyl)-1H-1,2,3-triazol-1-yl)benzoate (28) 
 
(20 mg, 16%). 1H NMR (400 MHz, DMSO-d6) δ= 11.11 (s, 1H), 8.76 (s, 1H), 8.16 (d, J = 
8.6 Hz, 2H), 8.07 (d, J = 8.6 Hz, 2H), 7.84 (s, 1H), 7.07 (s, 1H), 3.89 (s, 3H), 3.29 (t, 2H), 
2.76 (t, J = 7.5 Hz, 2H), 2.02 – 1.93 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ= 165.38, 
153.24, 147.91, 139.96, 135.92, 130.99, 129.04, 126.54, 120.50, 119.59, 99.52, 52.39, 








(29 mg, 23%). 1H NMR (400 MHz, DMSO-d6) δ= 12.94 (s, 1H), 8.77 (s, 1H), 8.44 (s, 1H), 
8.15 (d, J = 8.7 Hz, 2H), 8.06 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H), 2.79 (t, J = 7.5 Hz, 2H), 
2.65 (t, J = 7.3 Hz, 2H), 2.10 – 2.00 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ= 174.80, 
172.94, 165.37, 158.46, 147.70, 139.94, 130.99, 129.05, 120.57, 119.57, 52.39, 33.77, 
24.30, 23.83. tR=1.3 min, 99%. 
 
2.4.27: Methyl 4-(4-(3-(N-4-pyrimidinylamido)propyl)-1H-1,2,3-triazol-1-
yl)benzoate (30)  
 
(14 mg, 11%). 1H NMR (400 MHz, DMSO-d6) δ= 10.89 (s, 1H), 8.85 (s, 1H), 8.76 (s, 1H), 
8.62 (d, J = 5.7 Hz, 1H), 8.15 (d, J = 8.3 Hz, 2H), 8.09 – 8.03 (m, 3H), 3.89 (s, 3H), 2.77 
(t, J = 7.4 Hz, 2H), 2.54 (t, J = 7.3 Hz, 2H), 2.04 – 1.95 (m, 2H). 13C NMR (100 MHz, 
DMSO-d6) δ= 173.24, 165.37, 158.26, 158.18, 157.56, 147.89, 139.95, 130.99, 129.03, 





2.5: Procedure for protein thermal shift assay 
The thermal shift assay utilized a MicroAmp 96-well plate and 20 μM of gankyrin in buffer 
containing 8x Sypro Orange (Applied Biosystems). 5 mM of each compound were obtained 
from a DMSO stock, and a concentration of 300 μM was established with DMSO at a 
concentration of 5% vol/vol for each compound. Three trials were performed for each 
compound. Gankyrin unfolding was performed at a temperature range of 15 ˚C to 65 ˚C. 
SYPRO Orange fluorescence was tracked as a function of temperature in order to generate 
melting curves. The inflection point of the sigmoid is taken to be the melting temperature 
Tm. The difference in melting temperature (ΔTm) indicates the absolute value of difference 
between the melting temperature of gankyrin only and the melting temperature of gankyrin 
with molecule ligand bound. This difference in melting temperature indicates binding 












3. Results and discussion 
3.1: Chemistry 
3.1.1: Synthesis of cjoc42 derivatives (16-20) 
Scheme 1a 
 
aReagents: (a) HCl, NaNO2, NaN3. (b) 4-pentynol, sodium ascorbate, CuSO4, THF, H2O, 
tBuOH. (c) CH2Cl2, DMAP, TEA, p-tosyl Chloride. Ar = Various aromatic 
heterocycles. 
 The synthesis of cjoc42 derivatives 16-20 (Scheme 1) was initiated with the 
diazotisation of various aromatic heterocyclic amines (1-5) followed by addition of sodium 
azide to generate substituted azido intermediates 6-10. The obtained azido intermediates 
were then involved in a copper-catalysed alkyne-azide cycloaddition (CuAAC) with 4-
pentyn-1-ol in the presence of copper sulphate and sodium ascorbate to afford triazole 
intermediates 11-15 in modest yields (3%-42%) over 2 steps. These intermediates were 
then subjected to a nucleophilic substitution reaction with p-tosyl chloride in the presence 
of trimethylamine and 4-dimethylaminopyridine to generate various cjoc42 derivatives 16-





3.1.2: Synthesis of amide bond derivatives (23-30) 
Scheme 2a 
  
aReagents: (a) H2SO4, MeOH; (b) 5-hexynoic acid, sodium ascorbate, CuSO4, THF, H2O, 
tBuOH. (c) Pyridine, EDCI, Ar-NH2. Ar = Various aromatic heterocycles. 
 The synthesis of cjoc42 derivatives 23-30 (Scheme 2) was initiated with the acid-
catalysed methyl esterification of 4-azidobenzoic acid 21 to generate methyl 4-
azidobenzoate. This intermediate then underwent a copper-catalysed alkyne-azide 
cycloaddition (CuAAC) with 5-hexynoic acid in the presence of copper sulphate and 
sodium ascorbate to afford triazole intermediate 22 in good yield (70%). This intermediate 
was then reacted with various arylamines in the presence of 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide and pyridine or 4-Dimethylaminopyridine to generate 









3.2: Thermal shift assay 
All cjoc42 derivatives (16-20, 23-25, 27) were evaluated in a protein thermal shift 
assay in order to determine their relative gankyrin binding and compare them to cjoc42. 
The protein thermal shift assay determines the melting temperature of a protein (Tm), which 
is the temperature at which the protein denatures. At the melting point of a protein, it loses 
its quaternary, tertiary and secondary structure. This exposes the protein’s hydrophobic 
residues which in turn bind to the hydrophobic fluorescent dye (SYPRO orange). The 
fluorescence intensity is an indicator of the different stages of unfolding during the melting 
process. The melting temperature of a protein will be shifted when it binds effectively with 
a ligand as compared to a protein with no ligand bound. This shift in melting temperature 
(ΔTm) indicates if a ligand could be more or less effective in binding, where the larger the 
ΔTm, the more effective a ligand binds to the protein.  
To evaluate the relative gankyrin binding affinity of our cjoc42 derivatives, the ΔTm 
of cjoc42 bound to gankyrin was first determined, then the ΔTm of our synthesised cjoc42 
derivatives (16-20, 23-25, 27) were determined. The ΔTm of each cjoc42 derivative was 
then be compared to cjoc42 and ranked comparatively. All the synthesised cjoc42 
derivatives (16-20, 23-25, 27) with their respective ΔTm are shown in Figure 6 and Figure 
7 along with the ΔTm value of cjoc42. 
Cjoc42 derivatives 16-20 (Figure 6) exhibit a range of ΔTm values, indicating a 
range in relative binding affinities for gankyrin. Replacing the methyl benzoate ester of 
cjoc42 with various heteroaromatic systems 16-20 all resulted in slightly enhanced 
gankyrin binding affinity as compared to cjoc42. This enhanced affinity could be due to 
improved interactions with W46 and R41 at the binding site of gankyrin (Figure 5, Top). 
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An enhanced interaction with R41 could indicate an enhanced hydrogen bonding compared 
to cjoc42. An interaction with W46 (Figure 5, Top) involves pi-pi stacking between the 
non-polar indole of tryptophan and the heteroaromatic systems of these cjoc42 derivatives.  
For compounds 23-30, the sulfonate ester group of cjoc42 was replaced with an amide 
group, which had previously demonstrated a similar binding affinity to cjoc42. In addition, 
compounds 23-30 also replaced the tolyl group of cjoc42 with various heteroaromatic 
systems. Unfortunately, most of these compounds exhibited a decrease in gankyrin binding 
affinity as compared to cjoc42. Compound 24 was the one exception by exhibiting very 
similar gankyrin binding affinity as compared to cjoc42.  This data suggests that the 
introduction of more polar groups present in the heteroaromatic systems could negatively 
affect an interaction with W74. The non-polar indole of the W74 amino acid side chain could 
be the reason that there is a decrease in affinity between gankyrin and cjoc42 derivatives 






Figure 6. Thermal shift values for cjoc42 derivatives 16-20 for evaluation of cjoc42 
derivatives. Absolute values of ΔTm are plotted.  
 
Figure 7. Thermal shift values for cjoc42 derivatives 23-25, 27 for evaluation of cjoc42 
































Overall, compounds 16-20 exhibited improved gankyrin binding affinities as 
compared to cjoc42; whereas compounds 23-27 displayed similar or decreased gankyrin 

















4. ClogP of synthesised derivatives 
It has been previously observed that cjoc42 possesses poor water solubility, which 
could impair its ability to reach the desired target without precipitating. Therefore, it was 
sought to increase the hydrophilicity of the cjoc42 scaffold to enhance its bioavailability. 
The hydrophobicity and subsequent hydrophilicity of compounds 16-20, 23-30 could be 
predicted from the clogP values. logP is the partition coefficient of a compound between 
n-octanol and water; the logP of a compound indicates the ratio of its solubility in two 
solvents that are immiscible. ClogP is the calculated logP and it can be predicted by 
software such as ChemDraw, and the algorithm is developed by Biobyte. It is based on a 
programmable method of dissecting a solute structure into specific fragments. The program 
accesses values for the fragments which are measured in any one of five bonding 
environments which can account for differences in various bond types (e.g., aliphatic, 
benzyl, vinyl, styryl or aromatic). If the fragment is found, but not in the desired bond 
environment, it estimates the difference and reports it as ‘derived’. It then sums fragment 
values and makes important interaction corrections when fragments occur in proximity to 
one another. If the desired fragment structure is absent from the database, the program 
calculates it using a method (FRAGCALC) which examines all atoms and their neighbors 
and uses an equation based on eleven possible parameters which can raise or lower their 
hydrophobic contribution.49 Compounds that have high clogP values suggest they are 
highly hydrophobic and poorly hydrophilic, whereas low clogP values indicate the 
compounds are more water soluble and less lipid soluble. Compounds with desired drug-
likeness should have a clogP value no greater than 5. ClogP is important to the biological 
properties of the proposed compounds since they need to be hydrophilic enough to stay 
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solubilized in the bloodstream which is aqueous, while also being hydrophobic enough to 
pass through the phospholipid bilayer and effectively delivered to the cell. Therefore, 
balancing the hydrophobicity and hydrophilicity is crucial and was important to the design 
of our cjoc42 derivatives.  
LogP values can be powerful predictors of drug efficacy. When the logP is 
calculated, it typically is similar to its actual logP, however, it may deviate to some degree 
as well. For example, the logP value of ibuprofen is 3.9750, where clogP predicted from 
ChemDraw is 3.68. This shows the 2 numbers to be similar, but there is a slight difference 
between published logP and predicted clogP. clogP could be an indicator of drug efficacy 
when comparing the clogP values, however, the efficacy of drugs has to be demonstrated 
in controlled clinical trials by statistical evaluation. 
Cjoc42 has a clogP value of 3.4 as shown in Table 1, and a proposed compound 23 
has a clogP value of 2.57, which indicates a more water-soluble compound from its 
predicted properties. From the proposed compounds 23-25, it would be reasonable to 
predict that they all have a lower clogP value than cjoc42 due to the presence of multiple 
























































































Compounds 23-30 showed a more significant decrease in clogP values compared 
to cjoc42 than compounds 16-20. This could due to that fact that the benzoate ester is 
generally more hydrophobic than the various heteroaromatic replacements. Compounds 19, 
23-26, 28-30 also has lower clogP value than cjoc42, which could still be considered as 
further research basis since these compounds potentially possesses greater metabolic 
stability from their amide bond replacement of the sulphonate ester bond. 
Overall, replacing the methyl benzoate and tolyl groups of cjoc42 with various 
heteroaromatic groups resulted in a decrease in clogP which should improve the aqueous 








 A total of 14 cjoc42 derivatives were synthesised. with 5 derivatives (16-20) 
replaced the methyl benzoate of cjoc42 with heteroaromatic groups, and 8 derivatives (23-
30) replaced the sulfonate ester of cjoc42 with an amide bond as well as the tolyl group of 
cjoc42 with various heteroaromatic groups. Replacing the methyl benzoate of cjoc42 with 
heteroaromatic groups focused on optimising hydrogen bonding with R41 (Figure 5, Top), 
and improving the aqueous solubility of the compounds. Biophysical analysis in a protein 
thermal shift showed that replacing the methyl benzoate of cjoc42 with a 3-pyridine (23), 
4-pyridine (24) or 2-pyridine (25) group slightly improved gankyrin binding affinity as 
compared to cjoc42. These 3 derivatives are also predicted to display enhanced water 
solubility with a clogP of 2.57 for all three of them, where cjoc42 has a clogP of 3.4. 
Derivatives 23-25, 27 did not show enhanced gankyrin binding as compared to cjoc42, 
however, but they did predict enhanced water solubility due to their lower clogP values as 
compared to cjo42. These findings demonstrate that replacing the methyl benzoate of 
cjoc42 with various aromatic heterocycles can improve water solubility while also 
improving gankyrin binding, and that replacing the sulfonate ester of cjoc42 with an amide 
bond as well as the tolyl group of cjoc42 with various heteroaromatic groups could improve 







6. Future directions 
 Going forward, cjoc42 derivatives 16-20, 23-25, 27 will be evaluated in other 
biological assays for their ability to inhibit cancer cell migration, proliferation and 
metastasis in gankyrin-overexpressing cancer cell lines. Specifically, these compounds will 
be evaluated in hepatoblastoma cell lines (HepG2 and Hep3B), non-small cell lung cancer 
cell lines (A549) as well as breast cancer cell lines (MDA-MB-231), to observe their ability 
to inhibit cell proliferation and migration. Further optimization of the cjoc42 scaffold will 
be conducted by combining the optimal functional groups at different position in various 
cjoc42 derivatives for enhanced gankyrin binding and anti-cancer activity. Secondary 
biophysical assays will be included to further confirm gankyrin binding affinity, such as 
isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR). Cjoc42 
derivatives with improved efficacy in cell-based assays could ultimately prove to be future 












7.1: 1H and C13 NMR Spectra for intermediates (11-15) 






(371mg, 22%). 1H NMR (400 MHz, DMSO-d6) δ= 9.12 (d, J = 2.5 Hz, 1H), 8.67 (d, 2H), 
8.30 (ddd, J = 8.3, 2.5, 1.4 Hz, 1H), 7.64 (dd, J = 8.3, 4.8 Hz, 1H), 4.55 (s, 1H), 3.49 (t, J 
= 6.3 Hz, 2H), 2.76 (t, 2H), 1.87 – 1.77 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ= 














(314mg, 42%). 1H NMR (400 MHz, DMSO-d6) δ= 8.80 – 8.74 (m, 3H), 7.95 (d, J = 6.3 
Hz, 2H), 4.55 (t, J = 5.0 Hz, 1H), 3.48 (m, 2H), 2.76 (t, J = 7.7 Hz, 2H), 1.87 – 1.78 (m, 
2H). 13C NMR (100 MHz, DMSO-d6) δ= 149.14, 148.95, 144.79, 120.49, 114.25, 59.89, 
31.84, 21.59. 
 





(76mg, 3%). 1H NMR (400 MHz, DMSO-d6) δ= 8.64 (s, 1H), 7.81 (d, J = 3.4 Hz, 1H), 
7.74 (d, J = 3.4 Hz, 1H), 4.55 (t, J = 5.1 Hz, 0H), 3.46 (q, J = 11.7, 6.0 Hz, 2H), 2.76 (t, J 
= 7.7 Hz, 2H), 1.86 – 1.76 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 156.92, 148.64, 















(177mg, 10%). 1H NMR (400 MHz, DMSO-d6) δ 8.62 – 8.56 (m, 2H), 8.12 – 8.07 (m, 2H), 
7.53 (s, 1H), 4.55 (t, J = 5.1 Hz, 1H), 3.47 (q, J = 11.4, 6.2 Hz, 2H), 2.76 (t, J = 7.7 Hz, 
2H), 1.86 – 1.77 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 148.81, 148.67, 148.05, 
139.95, 123.93, 118.87, 113.44, 59.98, 32.03, 21.61.  
 
7.2: 1H and C13 NMR for Sulphonate Esters (16-20) 






(22 mg, 13%). 1H NMR (400 MHz, CDCl3) δ= 8.41 (d, J = 2.8 Hz, 1H), 7.91 (dd, J = 8.9, 
2.8 Hz, 1H), 7.76 (d, J = 8.0 Hz, 2H), 7.63 (s, 1H), 7.32 (d, J = 8.0 Hz, 2H), 6.87 (d, J = 
8.9 Hz, 1H), 4.07 (t, J = 6.0 Hz, 2H), 3.98 (s, 3H), 2.86 (t, J = 7.3 Hz, 2H), 2.41 (s, 3H), 
2.15 – 2.06 (m, 2H). 13C NMR (100 MHz, CDCl3) δ= 164.22, 146.98, 145.12, 139.20, 
133.10, 132.20, 130.10, 128.59, 128.11, 120.23, 112.00, 69.51, 54.31, 28.43, 21.84, 21.56. 













(34 mg, 19%). 1H NMR (400 MHz, DMSO-d6) δ= 8.78 (d, J = 6.3 Hz, 2H), 8.74 (s, 1H), 
7.92 (d, J = 6.4 Hz, 2H), 7.78 (d, J = 8.3 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 4.10 (t, J = 6.2 
Hz, 2H), 2.73 (t, J = 7.5 Hz, 2H), 2.35 (s, 3H), 2.05 – 1.96 (m, 2H). 13C NMR (100 MHz, 
DMSO-d6) δ= 151.60, 147.17, 144.86, 142.59, 132.28, 130.12, 127.57, 120.31, 113.32, 
69.90, 27.59, 21.01, 20.83. tR=0.49 min, 99%. 
 






(53 mg, 30%). 1H NMR (400 MHz, DMSO-d6) δ= 9.09 (d, J = 2.4 Hz, 1H), 8.68 (d, J = 
3.5 Hz, 1H), 8.61 (s, 1H), 8.28 (d, J = 8.3 Hz, 1H), 7.78 (d, J = 8.2 Hz, 2H), 7.65 (dd, J = 
8.3, 4.8 Hz, 1H), 7.44 (d, J = 8.1 Hz, 2H), 4.11 (t, J = 6.2 Hz, 2H), 2.73 (t, J = 7.5 Hz, 2H), 
2.35 (s, 3H), 2.05 – 1.96 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ= 149.46, 146.82, 
144.87, 141.01, 133.32, 132.32, 130.13, 127.58, 124.60, 120.70, 69.97, 27.73, 21.02, 20.86. 














(47 mg, 27%). 1H NMR (400 MHz, DMSO-d6) δ= 8.60 (d, J = 4.0 Hz, 1H), 8.53 (s, 1H), 
8.10 (q, J = 16.1, 8.5 Hz, 2H), 7.77 (d, J = 7.9 Hz, 2H), 7.53 (t, J = 5.5 Hz, 1H), 7.43 (d, J 
= 8.0 Hz, 2H), 4.08 (t, J = 6.3 Hz, 2H), 2.73 (t, J = 7.6 Hz, 2H), 2.35 (s, 3H), 2.05 – 1.96 
(m, 2H). 13C NMR (100 MHz, DMSO-d6) δ= 148.87, 148.56, 146.53, 144.85, 140.04, 














(69 mg, 57%). 1H NMR (400 MHz, DMSO-d6) δ= 8.57 (s, 1H), 7.82 (dd, J = 3.5, 0.9 Hz, 
1H), 7.80 – 7.74 (m, 3H), 7.44 (d, J = 8.0 Hz, 2H), 4.08 (t, J = 6.2 Hz, 2H), 2.73 (t, J = 7.5 
Hz, 2H), 2.37 (s, 3H), 2.05 – 1.96 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ= 156.80, 
147.10, 144.88, 140.56, 132.25, 130.12, 127.57, 119.88, 119.54, 69.86, 27.46, 21.04, 20.73. 










7.3: 1H and C13 NMR for Amides (23-30) 








(28.9 mg, 46%). 1H NMR (400 MHz, DMSO-d6) δ= 11.04 (s, 1H), 8.85 (s, 1H), 8.42 (d, 
J = 6.3 Hz, 2H), 8.12 (q, J = 17.7, 8.8 Hz, 4H), 7.72 (d, J = 6.5 Hz, 2H), 3.88 (s, 3H), 
3.15 (s, 1H), 2.78 (t, J = 7.4 Hz, 2H), 2.54 (t, J = 7.5 Hz, 2H), 2.06 – 1.96 (m, 2H). 13C 
NMR (100 MHz, DMSO-d6) δ= 171.37, 165.31, 147.92, 143.90, 140.68, 139.91, 135.82, 















(23.9 mg, 38%). 1H NMR (400 MHz, DMSO-d6) δ= 11.04 (s, 1H), 8.85 (s, 1H), 8.42 (d, J 
= 6.3 Hz, 2H), 8.12 (q, J = 17.7, 8.8 Hz, 4H), 7.72 (d, J = 6.5 Hz, 2H), 3.88 (s, 3H), 3.15 
(s, 1H), 2.78 (t, J = 7.4 Hz, 2H), 2.54 (t, J = 7.5 Hz, 2H), 2.06 – 1.96 (m, 2H). 13C NMR 
(100 MHz, DMSO-d6) δ= 172.05, 165.26, 149.87, 147.82, 145.84, 139.86, 130.85, 128.98, 

















(39 mg, 31%). 1H NMR (400 MHz, CDCl3) δ= 8.30 – 8.15 (m, 4H), 7.92 – 7.80 (m, 4H), 
7.74 – 7.66 (m, 1H), 7.07 – 7.00 (m, 1H), 3.96 (s, 3H), 2.93 (t, J = 7.2 Hz, 2H), 2.54 (t, J 
= 7.2 Hz, 2H), 2.25 – 2.14 (m, 2H). 13C NMR (100 MHz, CDCl3) δ= 171.99, 166.19, 155.22, 
151.06, 148.33, 140.41, 131.54, 130.21, 119.97, 119.86, 119.47, 114.91, 52.64, 36.83, 









7.3.4: Methyl 4-(4-(3-(N-2-thiazolamido)propyl)-1H-1,2,3-triazol-1-yl)benzoate (26) 
 
(66.5 mg, 52%). 1H NMR (400 MHz, CDCl3) δ= 8.17 (d, J = 8.6 Hz, 2H), 7.85 (s, 1H), 
7.80 (d, J = 8.6 Hz, 2H), 7.39 (d, J = 3.7 Hz, 1H), 6.93 (d, J = 3.6 Hz, 1H), 3.94 (s, 3H), 













(32 mg, 23%).1H NMR (400 MHz, CDCl3) δ= 8.51 (s, 1H, NH), 8.24 (s, 1H), 8.16 (d, J = 
8.5 Hz, 2H), 7.93 (d, J = 8.9 Hz, 1H), 7.87 (s, 1H), 7.78 (d, J = 8.5 Hz, 2H), 6.68 (d, J = 
8.9 Hz, 1H), 3.93 (s, 3H), 3.87 (s, 3H), 2.89 (t, J = 6.9 Hz, 2H), 2.47 (t, J = 7.0 Hz, 2H), 
2.17 – 2.08 (m, 2H). 13C NMR (100 MHz, CDCl3) δ= 171.59, 166.08, 161.01, 148.46, 
140.20, 138.57, 132.31, 131.55, 130.38, 129.18, 119.95, 119.63, 110.65, 53.75, 52.67, 













(20 mg, 16%). 1H NMR (400 MHz, DMSO-d6) δ= 11.11 (s, 1H), 8.76 (s, 1H), 8.16 (d, J = 
8.6 Hz, 2H), 8.07 (d, J = 8.6 Hz, 2H), 7.84 (s, 1H), 7.07 (s, 1H), 3.89 (s, 3H), 3.29 (t, 2H), 
2.76 (t, J = 7.5 Hz, 2H), 2.02 – 1.93 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ= 165.38, 
153.24, 147.91, 139.96, 135.92, 130.99, 129.04, 126.54, 120.50, 119.59, 99.52, 52.39, 








(29 mg, 23%). 1H NMR (400 MHz, DMSO-d6) δ= 12.94 (s, 1H), 8.77 (s, 1H), 8.44 (s, 1H), 
8.15 (d, J = 8.7 Hz, 2H), 8.06 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H), 2.79 (t, J = 7.5 Hz, 2H), 
2.65 (t, J = 7.3 Hz, 2H), 2.10 – 2.00 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ= 174.80, 
172.94, 165.37, 158.46, 147.70, 139.94, 130.99, 129.05, 120.57, 119.57, 52.39, 33.77, 
















(14 mg, 11%). 1H NMR (400 MHz, DMSO-d6) δ= 10.89 (s, 1H), 8.85 (s, 1H), 8.76 (s, 1H), 
8.62 (d, J = 5.7 Hz, 1H), 8.15 (d, J = 8.3 Hz, 2H), 8.09 – 8.03 (m, 3H), 3.89 (s, 3H), 2.77 
(t, J = 7.4 Hz, 2H), 2.54 (t, J = 7.3 Hz, 2H), 2.04 – 1.95 (m, 2H). 13C NMR (100 MHz, 
DMSO-d6) δ= 173.24, 165.37, 158.26, 158.18, 157.56, 147.89, 139.95, 130.99, 129.03, 
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